Ticker > Company >

Zim Laboratories share price

Zim Laboratories Ltd.

NSE: ZIMLAB BSE: 541400 SECTOR: Pharmaceuticals & Drugs  27.81 K   26   5

75.50
+0.10 (0.13%)
BSE: 29 Aug 04:01 PM

Price Summary

Today's High

₹ 75.5

Today's Low

₹ 73.3

52 Week High

₹ 128.45

52 Week Low

₹ 70

FinStar

Ownership Below Par
Stock price may face volatility due to ownership structure.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

367.88 Cr.

Enterprise Value

479.11 Cr.

No. of Shares

4.87 Cr.

P/E

39.58

P/B

1.52

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  49.56

CASH

0.82 Cr.

DEBT

112.05 Cr.

Promoter Holding

33.26 %

EPS (TTM)

₹  1.91

Sales Growth

2.78%

ROE

4.94 %

ROCE

8.35%

Profit Growth

-29.91 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year2.78%
3 Year4.47%
5 Year6.49%

Profit Growth

1 Year-29.91%
3 Year-3.36%
5 Year46.5%

ROE%

1 Year4.94%
3 Year8.85%
5 Year7.63%

ROCE %

1 Year8.35%
3 Year11.98%
5 Year11.22%

Debt/Equity

0.4608

Price to Cash Flow

7.27

Interest Cover Ratio

2.5468

CFO/PAT (5 Yr. Avg.)

2.44296639879785

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 33.26 0.00
Mar 2025 33.26 0.00
Dec 2024 33.26 0.00
Sep 2024 33.26 0.00
Jun 2024 33.26 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of 29.3617 days.
  • The company has a good cash flow management; CFO/PAT stands at 2.44296639879785.

 Limitations

  • The company has shown a poor profit growth of -3.36188965281501% for the Past 3 years.
  • The company has shown a poor revenue growth of 4.46552269367557% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 82 89.72 95.4 108.52 71.43
Total Expenditure 74.13 81.33 83.63 93.28 67.09
Operating Profit 7.88 8.39 11.77 15.24 4.34
Other Income 0.98 1.32 1.77 1.55 1.48
Interest 2.86 2.89 2.73 2.91 3.3
Depreciation 4.92 4.97 4.77 5.23 4.79
Exceptional Items 0 0 0 0 0
Profit Before Tax 1.08 1.85 6.03 8.65 -2.28
Tax 0.33 0.64 1.68 3.23 -0.59
Profit After Tax 0.76 1.22 4.35 5.42 -1.69
Adjusted EPS (Rs) 0.16 0.25 0.89 1.11 -0.35

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 303.63 329.49 396.53 365.47 375.64
Total Expenditure 266.82 291.56 345.34 325.37 332.37
Operating Profit 36.81 37.93 51.19 40.1 43.27
Other Income 2.45 4.51 6.43 4.69 5.62
Interest 10.89 8.31 5.58 6.92 11.39
Depreciation 14.61 14.84 16.13 14.83 19.89
Exceptional Items -5.18 0 0 0 0
Profit Before Tax 8.58 19.3 35.92 23.04 17.61
Tax 2.96 6.28 10.91 6.28 5.87
Net Profit 5.62 13.01 25.01 16.76 11.74
Adjusted EPS (Rs.) 1.15 2.67 5.13 3.44 2.41

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 16.24 16.24 48.73 48.73 48.73
Total Reserves 140.81 153.86 145.45 183.23 195.79
Borrowings 21.83 18.92 24.62 35.6 40.3
Other N/C liabilities -2.36 1.09 12.1 13.05 13.37
Current liabilities 141.23 146.76 110.24 161.9 166.2
Total Liabilities 317.75 336.88 341.15 442.5 464.39
Assets
Net Block 103.15 103.31 107.15 160.49 163.6
Capital WIP 4.56 5.1 17.84 23.52 44.05
Intangible WIP 5.9 6.33 8.42 16.73 21.61
Investments 8.08 8.18 8.18 8.23 13.04
Loans & Advances 11.25 11.64 20.4 15.51 4.97
Other N/C Assets 1.85 0.28 0.52 0.31 0.76
Current Assets 182.97 202.05 178.64 217.71 216.35
Total Assets 317.75 336.88 341.15 442.5 464.39
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 13.76 19.3 35.92 23.04 17.61
Adjustment 24.61 20.76 20.81 21.36 31.47
Changes in Assets & Liabilities -5.41 7.2 -14.52 -30.36 0.24
Tax Paid -1.06 -0.23 -6.98 -2.57 1.29
Operating Cash Flow 31.9 47.03 35.23 11.47 50.6
Investing Cash Flow -5.7 -14.42 -35.21 -71.94 -41.31
Financing Cash Flow -25.96 -32.97 0.55 59.53 -9.1
Net Cash Flow 0.23 -0.36 0.57 -0.94 0.19

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 33.26 33.26 33.26 33.26 33.26
anwar daud 27.37 27.37 27.37 27.37 27.37
hasan kamal 0.21 0.21 0.21 0.21 0.21
sabbah zulfiquar kamal 3.08 3.08 3.08 3.08 3.08
shabbar daud 0.09 0.09 0.09 0.09 0.09
tasneem anwar daud 0.06 0.06 0.06 0.06 0.06
zulfiquar murtuza kamal 2.45 2.45 2.45 2.45 2.45
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 66.74 66.74 66.74 66.74 66.74
bonanza business services... 2.54 2.54 2.54 2.54 2.54
dhoot industrial finance ... - - 1.35 1.44 1.44
dr iguer abdelmounaim 2.39 2.39 2.39 2.39 2.39
elizabeth mathew - - - - 12.02
investor education and pr... 3.03 3.03 3.59 3.59 3.58
jyoti bharat sheth - 1.38 1.38 1.38 1.35
laadki trading and invest... - 1.37 1.37 1.37 1.35
llp 0.09 0.26 0.21 0.13 0.16
zakir s vali 10.36 10.36 10.36 10.36 10.36
elizabeth mathew - - - 12.02 -
elimath advisors private ... - 3.37 3.17 - -
mathew cyriac 14.16 9.83 9.83 - -

Annual Reports

Title Link
Title Link
Annual Report 2023
Annual Report 2022
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit ACUITE RATINGS
Credit ACUITE
Credit ACUITE
Credit ACUITE
Credit CARE
Credit CRISIL
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY24
Concall Q4FY23
Concall Q3FY24
Concall Q1FY24
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY24
Presentation Q4FY22
Presentation Q4FY22
Presentation Q3FY22
Presentation Q2FY24
Presentation Q1FY25

Company News

Zim Laboratories' arm gets nod for investment of upto AED 4,50,000 in share capital of ZIM Scientific Office L.L.C 8 Aug, 3:09 PM Zim Laboratories - Quaterly Results 7 Aug, 7:49 PM Zim Laboratories - Quaterly Results 7 Aug, 7:49 PM ZIM Laboratories gets Marketing Authorization for Tamsulosin Hydrochloride and Dutasteride Capsules in Australia 4 Aug, 3:41 PM ZIM Laboratories informs about press release 21 Jul, 5:35 PM ZIM Laboratories gets marketing authorization for Rizatriptan Benzoate Orally Disintegrating Films 21 Jul, 2:30 PM ZIM Laboratories’ arm completes investment in ZIM Scientific Office 11 Jul, 3:43 PM Zim Laboratories informs about updates on acquisition 11 Jul, 3:17 PM Zim Laboratories informs about disclosure 19 Jun, 1:02 PM Zim Laboratories completes investment in SIA ZIM Laboratories 19 Jun, 12:39 PM Zim Laboratories - Quaterly Results 20 May, 8:30 PM Zim Laboratories - Quaterly Results 20 May, 8:30 PM Zim Laboratories informs about outcome of board meeting 28 Apr, 4:18 PM ZIM Laboratories inks pact with Globalpharma to commercialize oral thin film products 9 Apr, 6:14 PM ZIM Laboratories’ arm gets marketing authorization for Dimethyl Fumarate Capsules 20 Mar, 11:30 AM Zim Laboratories - Quaterly Results 10 Feb, 7:40 PM Zim Laboratories - Quaterly Results 10 Feb, 7:40 PM Zim Laboratories informs about closure of trading window 27 Dec, 5:11 PM ZIM Laboratories’ arm incorporates subsidiary in Dubai 16 Nov, 11:15 AM Zim Laboratories - Quaterly Results 9 Nov, 7:36 PM Zim Laboratories - Quaterly Results 9 Nov, 7:36 PM ZIM Laboratories gets nod to invest in equity shares of SIA ZIM Laboratories 1 Oct, 2:24 PM ZIM Laboratories informs about analyst meet 26 Aug, 5:11 PM Zim Laboratories informs about newspaper publication 5 Aug, 4:38 PM ZIM Laboratories gets nod to invest in SIA ZIM Laboratories 5 Aug, 10:13 AM Zim Laboratories - Quaterly Results 3 Aug, 6:28 PM Zim Laboratories - Quaterly Results 3 Aug, 6:28 PM ZIM Laboratories’ arm gets nod to market ‘Azithromycin for Oral Suspension’ in Portugal 23 Jul, 10:22 AM ZIM Laboratories invests Rs 68.25 lakh in ZIMTAS 2 Jul, 3:42 PM ZIM Laboratories informs about analyst meet 14 Jun, 2:31 PM ZIM Laboratories gets nod to invest Rs 40 lakh in SIA ZIM Laboratories 14 May, 9:59 AM ZIM Laboratories gets nod to invest Rs 2 crore in ZIMTAS 14 May, 9:39 AM Zim Laboratories - Quaterly Results 13 May, 9:29 PM Zim Laboratories - Quaterly Results 13 May, 9:29 PM Zim Laboratories informs about credit rating 6 Apr, 3:15 PM Zim Laboratories - Quaterly Results 29 Jan, 4:15 PM Zim Laboratories - Quaterly Results 29 Jan, 4:15 PM Zim Laboratories - Quaterly Results 29 Jan, 4:15 PM Zim Laboratories informs about details of loss of certificate 1 Jan, 5:02 PM Zim Laboratories informs about closure of trading window 29 Dec, 5:01 PM Zim Laboratories informs about loss of share certificate 22 Dec, 4:53 PM Zim Laboratories informs about loss of share certificates 5 Dec, 4:34 PM Zim Laboratories submits analyst meet intimation 4 Dec, 1:08 PM ZIM Laboratories informs about investor meet 25 Nov, 3:39 PM Zim Laboratories informs about analyst meet 21 Nov, 3:21 PM Zim Laboratories informs about transcript of earnings conference call 15 Nov, 12:38 PM Zim Laboratories - Quaterly Results 1 Nov, 8:02 PM Zim Laboratories - Quaterly Results 1 Nov, 8:02 PM Zim Laboratories informs about board meeting 21 Oct, 3:32 PM ZIM Laboratories incorporates step-down Subsidiary 14 Oct, 2:36 PM

Zim Laboratories Stock Price Analysis and Quick Research Report. Is Zim Laboratories an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Zim Laboratories. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Zim Laboratories has a PE ratio of 39.530250602915 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Zim Laboratories has ROA of 2.59% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Zim Laboratories has a Current ratio of 1.3017.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Zim Laboratories has a ROE of 4.9437%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Zim Laboratories has a Debt to Equity ratio of 0.4608 which means that the company has low proportion of debt in its capital.

  • Sales growth: Zim Laboratories has reported revenue growth of 2.7806% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Zim Laboratories for the current financial year is 11.5187196098345%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Zim Laboratories is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Zim Laboratories is Rs 1.9074. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Zim Laboratories in Ticker for free. Also, one can get the intrinsic value of Zim Laboratories by using Valuation Calculators, which are available with a Finology ONE subscription. 

Zim Laboratories FAQs

Q1. What is Zim Laboratories share price today?
Ans: The current share price of Zim Laboratories is Rs 75.4.

Q2. What is the market capitalisation of Zim Laboratories?
Ans: Zim Laboratories has a market capitalisation of Rs 367.39263756 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Zim Laboratories?
Ans: The PE ratio of Zim Laboratories is 39.530250602915 and the P/B ratio of Zim Laboratories is 1.52150487729083, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Zim Laboratories share?
Ans: The 52-week high share price of Zim Laboratories is Rs 128.9, and the 52-week low share price of Zim Laboratories is Rs 69.1.

Q5. Does Zim Laboratories pay dividends?
Ans: Currently, Zim Laboratories does not pay dividends. Dividend yield of Zim Laboratories is around 0%.

Q6. What are the face value and book value of Zim Laboratories shares?
Ans: The face value of Zim Laboratories shares is Rs 10, while the book value per share of Zim Laboratories is around Rs 49.5562. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Zim Laboratories?
Ans: Zim Laboratories has a total debt of Rs 112.0478 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Zim Laboratories?
Ans: The ROE of Zim Laboratories is 4.9437% and ROCE of Zim Laboratories is 8.348%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Zim Laboratories a good buy for the long term?
Ans: The Zim Laboratories long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Zim Laboratories undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Zim Laboratories appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Zim Laboratories’s financials?
Ans: You can review Zim Laboratories’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Zim Laboratories
X